» Articles » PMID: 28597832

Development and Validation of the HCV-MOSAIC Risk Score to Assist Testing for Acute Hepatitis C Virus (HCV) Infection in HIV-infected Men Who Have Sex with Men (MSM)

Overview
Journal Euro Surveill
Date 2017 Jun 10
PMID 28597832
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Current guidelines recommend hepatitis C virus (HCV) testing for HIV-infected men who have sex with men (MSM) with ongoing risk behaviour, without specifying the type of risk behaviour. We developed and validated the HCV-MOSAIC risk score to assist HCV testing in HIV-infected MSM. The risk score consisted of six self-reported risk factors identified using multivariable logistic regression using data from the Dutch MOSAIC study (n = 213, 2009-2013). Area under the ROC curve (AUC), sensitivity, specificity, post-test-probability-of-disease and diagnostic gain were calculated. The risk score was validated in case-control studies from Belgium (n = 142, 2010-2013) and the United Kingdom (n = 190, 2003-2005) and in cross-sectional surveys at a Dutch sexually transmitted infections clinic (n = 284, 2007-2009). The AUC was 0.82; sensitivity 78.0% and specificity 78.6%. In the validation studies sensitivity ranged from 73.1% to 100% and specificity from 56.2% to 65.6%. The post-test-probability-of-disease ranged from 5.9% to 20.0% given acute HCV prevalence of 1.7% to 6.4%, yielding a diagnostic gain of 4.2% to 13.6%. The HCV-MOSAIC risk score can successfully identify HIV-infected MSM at risk for acute HCV infection. It could be a promising tool to improve HCV testing strategies in various settings.

Citing Articles

Low Hepatitis C Virus Prevalence among Men Who Have Sex with Men Attending Public Health Services in The Netherlands.

Popping S, Haspels S, Gotz H, van der Meijden W, van den Elshout M, Rijnders B Viruses. 2023; 15(12).

PMID: 38140558 PMC: 10747767. DOI: 10.3390/v15122317.


Screening for Hepatitis C Virus Reinfection Using a Behaviour-Based Risk Score among Men Who Have Sex with Men with HIV: Results from a Case-Control Diagnostic Validation Study.

Hage K, van de Kerkhof M, Boyd A, Carson J, Newsum A, Matser A Pathogens. 2023; 12(10).

PMID: 37887764 PMC: 10610046. DOI: 10.3390/pathogens12101248.


Evaluating interventions to reduce behaviour associated with HCV reinfection in men who have sex with men: study protocol for a non-blinded, phase 2, randomised trial.

Hage K, Boyd A, Davidovich U, Zantkuijl P, Hoornenborg E, Matser A Trials. 2023; 24(1):193.

PMID: 36922871 PMC: 10015546. DOI: 10.1186/s13063-023-07161-y.


Development and Validation of a Risk Prediction Tool to Identify People at Greater Risk of Having Hepatitis C among Drug Users.

Huang G, Cheng W, Xu Y, Yang J, Jiang J, Pan X Int J Environ Res Public Health. 2022; 19(23).

PMID: 36497751 PMC: 9738321. DOI: 10.3390/ijerph192315677.


Internet-guided HCV-RNA testing: A promising tool to achieve hepatitis C micro-elimination among men who have sex with men.

Prinsenberg T, Schinkel J, Zantkuijl P, Davidovich U, Prins M, Van Der Valk M J Viral Hepat. 2022; 29(8):677-684.

PMID: 35583928 PMC: 9545250. DOI: 10.1111/jvh.13706.


References
1.
Wand H, Iversen J, Wilson D, Topp L, Maher L . Developing and validating a scoring tool for identifying people who inject drugs at increased risk of hepatitis C virus infection. BMJ Open. 2012; 2(1):e000387. PMC: 3253425. DOI: 10.1136/bmjopen-2011-000387. View

2.
. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. AIDS. 2010; 25(4):399-409. DOI: 10.1097/QAD.0b013e328343443b. View

3.
McCormack S, Dunn D, Desai M, Dolling D, Gafos M, Gilson R . Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2015; 387(10013):53-60. PMC: 4700047. DOI: 10.1016/S0140-6736(15)00056-2. View

4.
Hagan H, Jordan A, Neurer J, Cleland C . Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men. AIDS. 2015; 29(17):2335-45. PMC: 4640945. DOI: 10.1097/QAD.0000000000000834. View

5.
Martin N, Vickerman P, Dore G, Hickman M . The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for prevention. Curr Opin HIV AIDS. 2015; 10(5):374-80. PMC: 4659815. DOI: 10.1097/COH.0000000000000179. View